2 issues published
2026-05-26
Tebentafusp's phase III overall survival benefit in uveal melanoma validates TCR-based immune redirection as a new treatment paradigm, while a wave of MRD-guided, biomarker-selected, and circadian-timed trials signals oncology's accelerating shift from histology-driven to molecular-state-driven care.
Read issue →2026-05-21
AI mammography model validated across 3 continents outperforms all breast cancer risk tools — xAI review exposes reproducibility crisis
Read issue →